Sunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting Life Science Investing
Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures Life Science Investing
Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome Life Science Investing
Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference Life Science Investing
Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia Life Science Investing
Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obtaining Commitments of $3.5 Million in Payments to Company Life Science Investing
Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor Life Science Investing
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody Life Science Investing
Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Association Pharmaceutical Investing
